Our 1-Hour Strategy For R428

There is currently no consensus on a definition of hypoglycaemia in diabetes, with a variety of criteria being used to define hypoglycaemic events. The lack of a consistent definition makes it difficult to compare rates of hypoglycaemia across studies and therefore to quantify the problem in type 2 diabetes. The American Diabetes Association defines a biochemical threshold for hypoglycaemia as plasma glucose less than or equal to 3.9?mmol/l http://www.selleckchem.com/products/r428.html (70?mg/dl) (10). Diabetes UK defines hypoglycaemia as a blood glucose level of http://www.selleck.cn/products/3-methyladenine.html (6,12,13). The true incidence of self-treated hypoglycaemic episodes is difficult to determine as such events may often go unreported to the healthcare team. Some patients do not admit hypoglycaemic events to their doctor or nurse for fear of appearing unable to manage their condition or because of concerns over employment or fear of losing their driving licence. In one study only 15% of those who experienced a mild/moderate hypoglycaemic event reported the incident to their GP at their next scheduled visit (14). Data from cross-sectional studies indicate that self-treated hypoglycaemia is common in people with type 2 diabetes treated with oral glucose-lowering agents. In subjects with type 2 diabetes attending a specialised diabetes clinic, http://www.selleckchem.com/products/PF-2341066.html at least one episode of hypoglycaemic symptoms was reported during a 7-month follow-up period in 16.2% of people treated with either sulphonylurea, metformin or sulphonylurea plus metformin (15). Survey data from the East of England Ambulance Service NHS Trust suggests that, among people contacting the ambulance service regarding a diabetes-related event where the cause of the event was known, 30.6% of those events were because of hypoglycaemia (7). From the point of view of oral therapy, hypoglycaemic episodes occur more frequently in people receiving a sulphonylurea and for those whose glucose levels are being intensively controlled (16). In the UK over 600,000 people with type 2 diabetes are treated with a sulphonylurea, either alone or in combination with other agents (17). At the identified rates of hypoglycaemia associated with these agents, more than 5000 people treated with sulphonylureas will experience a severe hypoglycaemic event (requiring emergency intervention) over a 12?month period (17). Hypoglycaemia affects many aspects of life of people with diabetes, including employment, social interactions, sleep, driving, sport and leisure activities and adherence to therapy.